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Abstract
Background: Home-management of malaria (HMM) strategy improves early access of anti-malarial medicines to
high-risk groups in remote areas of sub-Saharan Africa. However, limited data are available on the effectiveness of
using artemisinin-based combination therapy (ACT) within the HMM strategy. The aim of this study was to assess
the effectiveness of artemether-lumefantrine (AL), presently the most favoured ACT in Africa, in under-five children
with uncomplicated Plasmodium falciparum malaria in Tanzania, when provided by community health workers
(CHWs) and administered unsupervised by parents or guardians at home.
Methods: An open label, single arm prospective study was conducted in two rural villages with high malaria
transmission in Kibaha District, Tanzania. Children presenting to CHWs with uncomplicated fever and a positive
rapid malaria diagnostic test (RDT) were provisionally enrolled and provided AL for unsupervised treatment at
home. Patients with microscopy confirmed P. falciparum parasitaemia were definitely enrolled and reviewed weekly
by the CHWs during 42 days. Primary outcome measure was PCR corrected parasitological cure rate by day 42, as
estimated by Kaplan-Meier survival analysis. This trial is registered with ClinicalTrials.gov, number NCT00454961.
Results: A total of 244 febrile children were enrolled between March-August 2007. Two patients were lost to
follow up on day 14, and one patient withdrew consent on day 21. Some 141/241 (58.5%) patients had recurrent
infection during follow-up, of whom 14 had recrudescence. The PCR corrected cure rate by day 42 was 93.0% (95%
CI 88.3%-95.9%). The median lumefantrine concentration was statistically significantly lower in patients with
recrudescence (97 ng/mL [IQR 0-234]; n = 10) compared with reinfections (205 ng/mL [114-390]; n = 92), or no
parasite reappearance (217 [121-374] ng/mL; n = 70; p ≤ 0.046).
Conclusions: Provision of AL by CHWs for unsupervised malaria treatment at home was highly effective, which
provides evidence base for scaling-up implementation of HMM with AL in Tanzania.
Background
Malaria still causes significant morbidity and mortality,
primarily among under-five children in sub-Saharan
Africa[1]. Access to prompt, effective malaria treatment
within 24 hours of the onset of symptoms is critical to pre-
vent mortality and reduce morbidity[2]. However, access
to effective anti-malarial medicines and other preventive
interventions is limited especially in remote rural areas of
sub-Saharan Africa [3-5]. To improve early access of effec-
tive anti-malarial treatment, the World Health Organiza-
tion (WHO) is promoting home-based management of
malaria (HMM) [5]. This strategy involves training of
community health workers (CHWs) to manage malarial
illness; access to effective, pre-packed anti-malarial medi-
cines; an effective communication strategy; and good
mechanism for supervision and monitoring [2]. Previous
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ment of uncomplicated malaria with chloroquine at com-
munity level significantly reduced malaria-related
morbidity and mortality [6-8].
Due to widespread resistance to chloroquine and sul-
phadoxine/pyrimethamine, most malaria-endemic coun-
tries in Africa and Asia have adopted the WHO
recommendation of introducing artemisinin-based com-
bination therapy (ACT) as first-line treatment for
uncomplicated Plasmodium falciparum malaria [9]. Arte-
mether-lumefantrine (AL) is presently the most widely
adopted ACT in Africa, including Tanzania [10].
Although AL has a relatively complex treatment regimen,
i.e. twice daily for 3 days, data from sub-Saharan Africa
at health facility level indicate that AL is highly effective
even with unsupervised administration [11-14]. More-
over, recent studies have shown that ACT can be suc-
cessfully integrated into the HMM strategy[15-17]. These
studies indicate that CHWs can safely dispense ACT
with suggestible good adherence by caregivers to the cor-
rect treatment schedules. However, concerns remain
among researchers and policy-makers due to limited data
on the effectiveness of using ACT in the HMM strategy
[18,19]. Another concern is that widespread presumptive
use of ACT may spur development of parasite tolerance/
resistance to these precious medicines[20].
To improve targeting of ACT to malaria infected patients
parasitological confirmation is essential at community level
in remote areas of sub-Saharan Africa, where a majority of
fever patients seek care. Antigen-based rapid malaria diag-
nostic tests (RDTs) may represent an important tool to
improve the diagnostic efficiency if incorporated in the
HMM strategy, considering that they are easy to use and
interpret and do neither require access to skilled techni-
cians nor electricity. Previous studies have shown that
RDTs can be accurately used by CHWs [21,22]. Recent
community-based studies in Tanzania and Ethiopia have
shown that the use of RDTs by CHWs improved targeting
of AL to malaria infected patients [17,23].
This study reports data on polymerase chain reaction
(PCR) corrected effectiveness of AL, when provided at
community level by CHWs and used unsupervised by
parents or guardians at home for treatment of uncom-
plicated P. falciparum malaria in under-five children,
during an extended follow-up period of 42 days, adher-
ence to treatment by measuring lumefantrine concentra-
tions on day 7 after initiation of treatment, and possible
selection of genetic markers associated with AL toler-
ance/resistance.
Methods
Study sites
The study was conducted between March-August 2007
in two neighbouring villages, Ngeta and Mwanabwito, in
rural Kibaha District, located about 50 km west of Dar
es Salaam, Tanzania. These two villages, with a total
population of 4,500 people, were among five villages
involved in a previous assessment of RDT use by CHWs
to improve targeting of ACT at the community level
[17]. The study sites were purposely selected based on
presence of active CHWs, accessibility during rainy sea-
son, and within three hours drive by car from Muhim-
bili University of Health and Allied Sciences (MUHAS),
Dar es Salaam. Malaria transmission is high, with peaks
related to the rainy seasons in May-July and December-
January. Plasmodium falciparum is the dominant para-
site species. There is one dispensary in each village and
most referrals are sent to Mlandizi Health Centre, situ-
ated at a distance of 9 to 10 kms from the selected vil-
lages. AL was the first-line treatment for uncomplicated
malaria at the time of the trial.
Selection and training of CHWs
After consultations with dispensary staff and village lea-
ders, six CHWs were selected among the existing 40
CHWs in the two villages. The selection of study CHWs
was based on gender balance, residential area and ability
to keep records. A three-day training workshop was
conducted at each village dispensary. The CHWs were
trained on how to recognize symptoms of both uncom-
plicated and severe malaria, as well as other febrile
childhood non-malaria diseases, such as pneumonia
(cough with fast breathing) and acute diarrhoea, as well
as in administration of AL and how to educate care-
givers on the use of AL. The CHWs were also trained
on how to perform and interpret RDT, i.e. Paracheck
Pf
®, according to the manufacturer’s instructions (Para-
check Pf, Orchid Biomedical Systems, Goa, India) and
simplified pictorial instructions (RDT job aid); prepare
thick blood smears and blood spots on filter paper
(Whatman 3MM) from finger prick blood samples; and
filling of case record forms. Each CHW was provided
with a weighing scale, a digital thermometer, pre-packed
AL tablets, paracetamol tablets, a dosing chart for AL,
RDTs, RDT job aid and a storage iron box. The CHWs
were responsible for referral of patients and storage of
the study drugs and other supplies for the study. During
the study period each CHW was given a monthly allow-
ance equivalent to 25 USD.
Patients
Children presenting to CHWs with symptoms suggestive
of uncomplicated malaria were screened for study elig-
ibility. Patients were enrolled if they met the following
inclusion criteria: age of 3-59 month; body weight of ≥5
kg; fever (≥ 37.5°C axillary) or a history of fever in the
preceding 24 hours; P. falciparum malaria confirmed by
RDT and later by microscopy; able to ingest tablets
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sion of written informed consent by a parent or guar-
dian, and absence of any general danger signs of severe
disease (convulsions, lethargic/unconscious, unable to
drink/breast feed, vomiting everything). Patients with
negative RDT test results and/or signs of severe disease
were to be immediately referred to the village dispensary
for further management.
Study design, treatments and procedures
This was an open label, single arm prospective study,
assessing PCR corrected parasitological cure rate of a
six-dose treatment with unsupervised intake of AL pro-
vided by CHWs to under-five children with uncompli-
cated P. falciparum infection with an extended follow-
up of 42 days. Patients fulfilling the inclusion criteria
were provisionally enrolled based on a positive RDT
result and provided AL treatment in standard doses
according to the body weight: one tablet per dose for
patients weighing 5-14.9 kg (yellow blister pack) and
two per dose for 15-24 kg (blue blister pack). Every blis-
ter pack had pictures showing how the drug should be
given. The first dose was given under supervision of the
CHWs. If patients vomited the first dose within 30 min;
administration of the full dose was repeated. The other
five doses were given by the parents/caregivers at home.
Standardized verbal instructions on dose, frequency and
advice to combine treatment with fatty meals or breast
milk were given by CHWs. Paracetamol was provided to
all febrile patients. Parents or guardians were instructed
to report to the CHWs or the village dispensary if the
child’s condition had not improved after 48 hours or if
worsened at any time. Anti-malarial medicines and
other drugs in the study were provided by the research
project free-of-charge.
Blood smears were stained with Giemsa and read at
the Department of Parasitology, MUHAS. The results
were provided to the CHWs and patients within three
days of sampling. Children with positive RDTs but nega-
tive blood smear results were excluded from the study
and referred to the dispensary. Children with microsco-
pically confirmed malaria were definitely enrolled. Par-
ents or guardians were requested to bring their children
back to the CHWs on days 7, 14, 21, 28, 35 and 42 or
on any day that they felt ill. At each visit, children were
assessed for symptoms, possible adverse events, and
body temperature. Finger prick blood samples were col-
lected for microscopy (thick blood smears) and PCR
analysis (on Whatman filter paper), respectively, at day
of enrolment and at each follow-up visit. In addition,
the research team leader collected blood samples (100
μl taken by capillary tube) on pre-treated filter papers
on day 7, which were used later for determination of
lumefantrine blood concentrations. If patients did not
return for scheduled follow-up visits, they were actively
followed-up in their homes the next day.
Patients with recurrent infections within 14 days after
initiation of AL treatment and in children who devel-
oped symptoms or signs of severe malaria during fol-
low-up were withdrawn from the study, and referred to
the village dispensary or Mlandizi health centre for res-
cue treatment with quinine. In children with clinical
failure (non-severe malaria) after day 14 or parasitologi-
cal failure day 42 after the initial therapy were retreated
with AL in accordance with national guidelines [24].
Laboratory procedures
Microscopy
A l lt h i c kb l o o ds m e a r sw e r ep i c k e du pf r o mC H W sb y
the research team within 24 hours after collection and
stained with 5% Giemsa for 20 minutes at MUHAS.
Two qualified microscopists independently read all thick
blood smears. The parasite density was estimated by
counting the number of asexual parasites per 200 (for
gametocytes 1,000) white blood cells and calculating
parasites per μL, assuming a white blood cell count of
8,000 per μL. A smear was declared negative if no asex-
ual parasites were seen after examining 200 high power
fields. Disagreement in readings (positive versus nega-
t i v e )o ra na tl e a s tt w of o l dd i f f e r e n c ei np a r a s i t ed e n -
sity, a third decisive microscopy reading, again blinded
was to be done.
Molecular analysis
Distinction between recrudescence and reinfection
events was performed by the use of stepwise genotyping
of the P. falciparum genes merozoite surface protein-2
(msp2), glutamate-rich protein (glurp)a n dmsp1 using
standard protocols [25]. Recrudescences were defined as
samples containing at least one matching allelic band in
all markers, from paired samples collected on day of
enrolment (D0) and day of recurrent infection (R0). A
reinfection was defined as the absence of any matching
allelic band in at least one marker in the paired blood
samples.
Single nucleotide polymorphisms (SNPs) in the P. fal-
ciparum chloroquine resistance transporter gene (pfcrt)
K76T and P. falciparum multidrug resistance gene 1
(pfmdr1) N86Y, previously associated with quinoline
resistance, were analysed according to established ApoI
restriction enzyme-based PCR restriction fragment
length polymorphism (PCR-RFLP) protocols [26].
Determination of blood lumefantrine concentrations
Capillary blood samples (100 μL, taken by heparinized
micropipette) were applied on filter papers pre-treated
with 0.75 M tartaric acid. These blood samples were
dried, put in small zipped plastic bags and frozen at -20°
C the day after sampling. After completion of the field
trial they were transported to the Bioanalytics and
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den, where lumefantrine blood concentrations were
measured by solid-phase extraction and liquid chroma-
tography [27].
Outcome measures
The day-42 PCR corrected parasitological cure rate was the
primary efficacy outcome, i.e. proportion of patients with
clearance of asexual parasitaemia within seven days of
initiation of treatment, without recrudescence within 42
days after initiation of treatment, and without use of rescue
medication for clinical signs of malaria. Secondary out-
comes included PCR corrected parasitological cure rates
on days 14 and 28 after treatment; risk of reinfections after
treatment; day 7 blood lumefantrine concentrations; selec-
tion of genetic markers (SNPs) in pfcrt and pfmdr1;a n d
adverse events defined as signs and symptoms that
occurred or increased in severity after treatment started.
Statistical analysis
Assuming that AL treatment provided by CHWs would
result in less than 85% PCR corrected parasitological
cure rate by day 42. According to the WHO protocol
[28], with an estimated treatment failure lower than
15%, confidence interval of 95%, a precision of 10% and
a 20% drop out rate, the minimum sample size needed
was at least 60 patients. To compare effectiveness data
from this study with both efficacy and effectiveness data
from a separate study conducted at health facility level
[29], a total of 200 under-five children were recruited.
Data were double-entered and validated using EpiData
software, version 3.02 (EpiData Association, Odense
Denmark) and analysis was performed using Stata 10.0
(StataCorp, College Station, Texas, USA). Proportions
were compared with X
2 test or Fisher’s exact test as
appropriate. All patients with microscopically confirmed
P. falciparum malaria who had taken at least one full
dose of the study medication and had at least one post-
baseline efficacy assessment were included in the ana-
lyses. Cure rates and cumulative proportion of recurrent
parasitaemia were estimated by Kaplan-Meier survival
analysis. Data were censored for patients who were lost
to follow-up or for patients with reinfections, and inde-
terminate or missing PCR results at the last day seen.
Ethical clearance
The study was approved by the National Institute for
Medical Research in Tanzania and Regional Ethics Com-
mittee Stockholm, Sweden, and was registered with
identifier NCT00454961[30]. Before enrolment, written
informed consent was obtained from the parents or
legal guardians of the children.
Results
Between March and July 2007, 398 febrile children were
screened for study eligibility, 300 (75.4%) were provi-
sionally enrolled based on a positive RDT, of whom 250
(83.3%) were P. falciparum positive by microscopy (Fig-
ure 1). Of these 250 patients, 244 (97.6%) met the inclu-
sion criteria and were thus definitely enrolled (Figure 1).
Three children (<2%) did not complete the 42-day fol-
low-up period (Figure 1); one due to withdrawn consent
on day 21 and two children moved from the study area
on day 14. Baseline demographic characteristics are
shown in Table 1. A majority of patients, 216/244
(88.5%), had parasite density ≥2,000/μL blood, and one
child had parasite density >200,000/μL, but had no gen-
eral danger signs indicating severe disease.
Effectiveness assessment
No early treatment failure was reported. On day 7, all
patients were afebrile, but 7/244 (2.9%) were still parasi-
taemic. PCR analysis of these seven patients revealed
four reinfections, two recrudescences and one indeter-
minate result. By day 42, some 141/241 (58.5%) patients
had recurrent parasitaemia (Figure 2), of whom 32
(22.7%) presented with fever. Parasite genotyping
showed that 118 (84%) were due to reinfection, 14
(10%) recrudescence and 9 (6%) indeterminate results.
The PCR corrected cure rates at days 14, 28 and 42
were 97.9%, 95.1% and 93.0%, respectively (Table 2).
There was no statistically significant difference in med-
ian (range) time to recrudescent infections, i.e. 21 (7-42)
days compared to 28 (7-42) days for reinfections (p =
0.41). Three (21%) of the 14 children with recrudescent
infection were identified after 28 days of follow-up. At
baseline, eight patients carried gametocytes (Table 1).
During follow-up only one gametocyte carrier was
observed on day 7.
Day 7 lumefantrine concentrations
A total of 177 of 244 (73%) patients had blood lumefan-
trine concentrations measured on day 7 after initiation
of treatment. The median (range) lumefantrine concen-
tration on day 7 was 205 ng/mL (0-1887). The median
lumefantrine concentration was significantly lower in
patients with recrudescence (97 ng/mL [IQR 0-234]; n =
10) than in those with reinfections (205 ng/mL [114-
390]; n = 92), or no parasite reappearance (217 [121-
374] ng/mL; n = 70; p ≤ 0.046) (Figure 3). Overall, 63%
(112/177) of patients had lumefantrine concentrations
<280 ng/mL[31]. Of the 10 patients with recrudescent
infections analysed, eight had lumefantrine concentra-
tions <280 ng/mL. All seven patients with parasitaemia
on day 7 had lumefantrine concentration <280 ng/mL.
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Proportions of parasites carrying pfmdr1 N86 and pfcrt
K76 at baseline and recurrent parasitemia are presented
in Table 3. The pfmdr1 86N allele was observed to be
selected among recurrent infections (p < 0.01), while the
pfcrt K76T SNP did not show any pattern of selection
upon AL administration.
Adverse events
AL was well tolerated. No deaths occurred. Two serious
adverse events were reported, both were due to severe
malaria on days 14 and 42. In total 162 adverse events
(mild or moderate in severity) were reported during fol-
low-up, the most common being fever (34%), cough
(34%) and diarrhoea (12%). These events were consid-
ered unrelated to AL treatment.
Discussion
The results from this study showed that intake of unsu-
pervised AL used in HMM was highly effective and
well-tolerated for the treatment of acute uncomplicated
P. falciparum malaria in Tanzanian children below five
years of age. This study is the first to assess the PCR
corrected cure rate achieved with ACT in the context of
HMM after an extended follow-up to 42 days. A pre-
vious multicentre study showed high effectiveness of
ACT used in HMM [19]. However, this study had only
28 days follow-up. Importantly, the results are consistent
with previous effectiveness studies conducted at health
facility level in sub-Saharan Africa [11-14].
However, a concern is the limited post-treatment pro-
phylactic effect of AL in this high malaria transmission
area, which resulted in more than half of the patients hav-
ing recurrent infections within the 42-day follow-up per-
iod. A great majority of all recurrent infections were due
to reinfections, when assessed with stepwise genotyping
5'7QHJDWLYH
DVVHVVHGIRUHOLJLELOLW\
FRPSOHWHGVWXG\
HQUROOHG
LQHOLJLEOH
JDPHWRF\WHVRQO\
VHYHUHPDODULD
UHIXVHGFRQVHQW
ORVWWRIROORZXS
FRQVHQWZLWKGUDZQ
5'7SRVLWLYH
%6SRVLWLYH
%6QHJDWLYH
Figure 1 Flow of the patients through the study.
Table 1 Baseline demographic characteristics
Characteristic (N = 244)
Male 131 (53.7%)
Age, median months (range) 31.3 (6.0-62.0)
Weight, median kg (range) 11.7 (6.0-23.0)
Number of children weighing 5-<15 kg 190 (77.9%)
Number of children weighing 15-<25 kg 54 (22.1%)
Asexual parasitaemia, geometric mean parasite/μl
(range),
19054 (400-
240000)
Number of patients with parasite density ≥ 2000/μl 216 (88.5%)
Temperature, °C, mean 38.0
Gametocyte carriage 8 (3.3%)
Vomiting on day 0 89 (36.5%)
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with little or no immunity to malaria may have a shorter
post-treatment prophylactic effect compared to older chil-
dren and adults [32]. Similar high risk of recurrent infec-
tions after AL treatment has been reported in other high
transmission areas in sub-Saharan Africa [33-36]. This
highlights the need of integrated approaches for malaria
control. Recent data indicate that the use of ACT, sup-
ported by vector control interventions including long-last-
ing insecticide-treated nets (LLINs) significantly reduced
malaria-associated morbidity and mortality in seven
malaria-endemic countries, including Zanzibar islands in
Tanzania [37].
Adherence to AL treatment in this trial was assessed
by measuring day 7 lumefantrine levels, a potentially
more reliable method of measuring adherence to treat-
ment than the use of questionnaires, which has a poten-
tial for recall bias [38,39]. The method applied in this
study has shown adequate sensitivity for quantification
of lumefantrine from capillary blood samples collected
on pre-treated filter paper[27]. Its minimal invasiveness
and overall simple sampling procedure makes it a feasi-
ble field method in clinical trials conducted in remote
areas. The observed median day 7 lumefantrine concen-
tration of 205 ng/mL was similar to the concentrations
achieved with unsupervised intake of AL in two recent
health facility based studies conducted in the neighbour-
ing Bagamoyo District and Malawi[29,38]. Moreover, the
proportion of children (over 60%) that had a day 7
lumefantrine concentration <280 ng/mL, a cut-off level
previously associated with increased risk of treatment
failure [31], was similar to un s u p e r v i s e dg r o u p sa tt h e
health facility based studies [11,40]. The absorption of
lumefantrine is known to have a high variability and
suboptimal drug levels could potentially result from
inadequate fat intake [11,40]. Although, in this study, fat
intake was not assessed, caregivers were encouraged to
accompany each AL dose with milk or fat-containing
food. Low blood lumefantrine concentrations increase
the risk of treatment failure and reinfections [40-43]. In
this study all recrudescent infections and reinfections
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Figure 2 Kaplan Meier curve showing cumulative proportion of children with recurrent parasitaemia during follow-up after
artemether-lumefantrine treatment.
Table 2 PCR uncorrected and corrected cure rates as
estimated by Kaplain-Meier analysis
Cure rate rate, % (95%CI)
Day 14 PCR uncorrected 91.8 (87.5-94.6)
Day 14 PCR corrected 97.9 (95.1-99.1)
Day 28 PCR uncorrected 60.2 (53.7-66.1)
Day 28 PCR corrected 95.1 (91.4-97.3)
Day 42 PCR uncorrected 41.5 (35.3-47.7)
Day 42 PCR corrected 93.0 (88.3-95.9)
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trine concentration <280 ng/mL. Similarly, a majority of
patients with recrudescent infections during the 42 days
follow-up had day 7 blood lumefantrine concentration
<280 ng/mL. To improve adherence to unsupervised AL
treatment therefore represents a key challenge for
malaria control programmes in Africa to reduce the risk
of adverse treatment outcome in children with uncom-
plicated malaria infection.
In high transmission areas, residual low/sub-therapeu-
tic concentrations of the long acting partner drug in
ACT create strong selective pressure for development
and spread of tolerant/resistant parasites [44,45]. In this
study, similarly to previous observations, there was sig-
nificant selection of the pfmdr1 N86 allele in recurrent
infections after AL treatment [46-50]. This data further
support the potential importance of this gene in parasite
response to this ACT. Less clear is the involvement of
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Figure 3 Box plots of day 7 lumefantrine concentrations versus endpoints after treatment with artemether-lumefantrine.
Table 3 Frequencies of the analyzed single-nucleotide polymorphism (SNPs), before treatment (D0) and in recurrent
infections after treatment with artemether-lumefantrine (R0)
Frequencies, (pure+mix)/total*, % (95%CI)
pfmdr1 N86 pfcrt K76
D0
All patients (115+56)/234 73.1 (67.4-78.8)
a (152+41)/232 83.2 (78.3-88.0)
Patients with recrudescence during follow-up (5+8)/13 100.0 (100.0-100.0) (7+5)/13 92.3 (75.6-100.0)
Patients with reinfection during follow-up (53+33)/115 74.8 (66.7-82.8)
b (71+23)/113 83.2 (76.2-90.2)
R0
All patients (99+30)/138 93.5 (89.3-97.7)
a (92+15)/126 84.9 (78.6-91.3)
Patients with recrudescence (12+2)/14 100.0 (100.0-100.0) (9+2)/13 84.6 (61.9-100.0)
Patients with new infection (79+25)/112 92.9 (88.0-97.7)
b (74+13)/104 83.7 (76.4-90.9)
* denotes the total no of successful analyses; CI, confidence interval.
* denotes the total no of successful analyses; CI, confidence interval.
aStatistically significant increase between baseline and all recurrent infections, P < 0.0001.
bStatistically significant increase between baseline and only reinfections, P = 0002.
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ducted in Bagamoyo District, Tanzania [46], a significant
selection of the pfcrt K76 allele in recurrent infections
after AL treatment was not observed. This might be due
to lack of statistical power of the present study, taking
in account the high baseline prevalence of the pfcrt K76
(> 80%). It can also reflect that although the potential of
pfcrt K76T to modulate is by now well supported in
vitro [46,51], its in vivo importance might be less gen-
eral than the observed for pfmdr1 86N, being more
dependent on the overall genetic makeup of the studied
parasite populations.
Selecting study sites that were geographically accessi-
ble within three hours by car from Dar es Salaam might
have introduced a selection bias. However, the selected
villages were not different from those not included in
the study in terms of number and quality of CHWs.
Moreover, the weekly follow-up and supervision by
researchers may have influenced the behaviour of
CHWs and caregivers and resulted in improved adher-
ence, however, supervision and monitoring of the com-
munity activities is one of the key components of the
HMM strategy.
Conclusions
In conclusion, this study showed high PCR corrected
effectiveness of AL used in HMM during an extended
follow-up of 42 days, which provides evidence for scal-
ing-up implementation of HMM strategy with AL in
Tanzania. However, the risk of recurrent infections after
AL treatment was high, why integration of ACT with
preventive interventions is critical for improved malaria
control. The in vivo selection of genetic markers asso-
ciated with drug resistance confirms that AL is vulner-
able to selection of resistance-related polymorphisms in
areas of high malaria transmission. It is crucial that the
HMM strategy incorporates components for monitoring
adherence to ACT treatment and drug resistance.
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